benralizumab   Click here for help

GtoPdb Ligand ID: 7674

Synonyms: BIW-8405 | Fasenra® | KHK4563 | MEDI-563
Approved drug Immunopharmacology Ligand
benralizumab is an approved drug (FDA (2017), EMA (2018))
Compound class: Antibody
Comment: Benralizumab is a humanized, afucosylated mAb targeting the IL5Rα which is expressed by cells of the eosinophil lineage. The antibody is afucosylated (ie has fucose containing oligosaccharide side-chains removed) to improve structure, stability, and biological function.
Peptide sequence information for this antibody is available from its IMGT/mAb-DB link.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: benralizumab

References
1. Castro M, Wenzel SE, Bleecker ER, Pizzichini E, Kuna P, Busse WW, Gossage DL, Ward CK, Wu Y, Wang B et al.. (2014)
Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study.
Lancet Respir Med, 2 (11): 879-90. [PMID:25306557]
2. Drugs.com. 
FDA Approves Fasenra.
Accessed on 16/11/2017. Modified on 16/11/2017. drugs.com, https://www.drugs.com/newdrugs/fda-approves-fasenra-benralizumab-severe-eosinophilic-asthma-4633.html?utm_source=ddc&utm_medium=email&utm_campaign=FDA+Approves+Fasenra+%28benralizumab%29+for+Severe+Eosinophilic+Asthma
3. European Medicines Agency. 
Fasenra.
Accessed on 16/11/2017. Modified on 16/11/2017. ema.europa.eu, http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/004433/smops/Positive/human_smop_001219.jsp&mid=WC0b01ac058001d127&source=homeMedSearch&category=human
4. FitzGerald JM, Bleecker ER, Nair P, Korn S, Ohta K, Lommatzsch M, Ferguson GT, Busse WW, Barker P, Sproule S et al.. (2016)
Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial.
Lancet, 388 (10056): 2128-2141. [PMID:27609406]
5. Ghazi A, Trikha A, Calhoun WJ. (2012)
Benralizumab--a humanized mAb to IL-5Rα with enhanced antibody-dependent cell-mediated cytotoxicity--a novel approach for the treatment of asthma.
Expert Opin Biol Ther, 12 (1): 113-8. [PMID:22136436]
6. Koike M, Spitalny GL, Wheeler A, White B. (2013)
Methods of reducing eosinophil levels.
Patent number: US8501176. Assignee: Medimmune, Llc, Biowa, Inc.. Priority date: 14/05/2007. Publication date: 06/08/2013.
7. Mukherjee M, Sehmi R, Nair P. (2014)
Anti-IL5 therapy for asthma and beyond.
World Allergy Organ J, 7 (1): 32. [PMID:25709744]